Alembic Pharmaceuticals Ltd – 533573 – Announcement under Regulation 30 (LODR)-Press Release / Media Release

Source: BSE

Company: Alembic Pharmaceuticals Ltd

With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Approval for Dorzolamide Hydrochloride Ophthalmic Solution USP, 2%.

Click to View: Alembic Pharmaceuticals Ltd

0 Reviews

Write a Review

Read Previous

Confidence Petroleum India Ltd – 526829 – Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Read Next

Panasonic Energy India Company Ltd – 504093 – Corporate Action – Fixes Book Closure For Annual General Meeting For Payment Of Dividend For The FY 2018-19.

Leave a Reply

Your email address will not be published. Required fields are marked *

Translate »